Literature DB >> 29803692

Single- Versus Double-Lung Transplantation in Pulmonary Fibrosis: Impact of Age and Pulmonary Hypertension.

Mauricio A Villavicencio1, Andrea L Axtell2, Asishana Osho2, Todd Astor3, Nathalie Roy2, Serguei Melnitchouk2, David D'Alessandro2, George Tolis2, Yuval Raz3, Isabel Neuringer3, Thoralf M Sundt2.   

Abstract

BACKGROUND: Double-lung transplantation (DLT) has better long-term outcomes compared with single-lung transplantation (SLT) in pulmonary fibrosis. However, controversy persists about whether older patients or patients with high lung allocation scores would benefit from DLT. Moreover, the degree of pulmonary hypertension in which SLT should be avoided is unknown.
METHODS: A retrospective analysis using the United Network for Organ Sharing database was performed in all recipients of lung transplants for pulmonary fibrosis. Kaplan-Meier survival for SLT versus DLT was compared and stratified by age, allocation score, and mean pulmonary artery pressure. Cox regression and propensity-matching analyses were performed.
RESULTS: Between 1987 and 2015; 9,191 of 29,779 lung transplants were performed in pulmonary fibrosis. Ten-year survival rates were 55% for DLT and 32% for SLT (p < 0.001). When stratified by age, DLT recipients had improved survival at all age cutoffs, except age ≥70 years. In addition, DLT recipients had improved survival across all lung allocation scores (<45, ≥45, ≥60, ≥75) and all pulmonary artery pressure categories (<25, ≥25, ≥30, ≥40 mm Hg). Among DLT recipients, pulmonary artery pressure and allocation score did not affect survival. Among SLT recipients, a pressure ≥25 mm Hg did not influence survival. Conversely, patients with a pressure ≥30 mm Hg and an allocation score ≥45 had decreased survival. On Cox regression and on propensity matching, DLT had improved survival compared with SLT.
CONCLUSIONS: In pulmonary fibrosis, DLT has improved survival compared with SLT and should be considered the procedure of choice in patients younger than 70 years of age. SLT in patients with mean pulmonary artery pressure ≥30 mm Hg and an allocation score ≥45 should be discouraged.
Copyright © 2018 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29803692     DOI: 10.1016/j.athoracsur.2018.04.060

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  8 in total

1.  Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation.

Authors:  Lorriana E Leard; Are M Holm; Maryam Valapour; Allan R Glanville; Sandeep Attawar; Meghan Aversa; Silvia V Campos; Lillian M Christon; Marcelo Cypel; Göran Dellgren; Matthew G Hartwig; Siddhartha G Kapnadak; Nicholas A Kolaitis; Robert M Kotloff; Caroline M Patterson; Oksana A Shlobin; Patrick J Smith; Amparo Solé; Melinda Solomon; David Weill; Marlies S Wijsenbeek; Brigitte W M Willemse; Selim M Arcasoy; Kathleen J Ramos
Journal:  J Heart Lung Transplant       Date:  2021-07-24       Impact factor: 13.569

2.  Single versus double lung transplantation for fibrotic disease-systematic review.

Authors:  Ashley R Wilson-Smith; Yong Sul Kim; Georgina E Evans; Tristan D Yan
Journal:  Ann Cardiothorac Surg       Date:  2020-01

3.  Single versus bilateral lung transplantation in idiopathic pulmonary fibrosis: A systematic review and meta-analysis.

Authors:  Diandian Li; Yi Liu; Bo Wang
Journal:  PLoS One       Date:  2020-05-21       Impact factor: 3.240

4.  Accuracy of echocardiography and chest tomography for pulmonary hypertension screening in patients awaiting lung transplantation.

Authors:  Luiza Helena Degani-Costa; João Paulo de Assis; Pedro Paulo Pisaniello Gonçalves; Fernanda Gushken; Gilberto Szarf; José Eduardo Afonso Junior
Journal:  Einstein (Sao Paulo)       Date:  2021-12-20

5.  The outcome of lung transplantation for end-stage pulmonary diseases with pulmonary hypertension: a single-center experience.

Authors:  Shilong Wu; Guilin Peng; Chenyang Xu; Xiuhua Li; Wenfa Jiang; Qing Ai; Chao Yang; Don Xiao; Bing Wei; Weizhe Huang; Xin Xu; Jianxing He
Journal:  J Thorac Dis       Date:  2022-04       Impact factor: 2.895

Review 6.  Idiopathic pulmonary fibrosis: Current and future treatment.

Authors:  Daniel S Glass; David Grossfeld; Heather A Renna; Priya Agarwala; Peter Spiegler; Joshua DeLeon; Allison B Reiss
Journal:  Clin Respir J       Date:  2022-01-10       Impact factor: 1.761

Review 7.  Targeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis.

Authors:  Hongbo Ma; Shengming Liu; Shanrui Li; Yong Xia
Journal:  Front Pharmacol       Date:  2022-06-03       Impact factor: 5.988

Review 8.  Research Progress in the Molecular Mechanisms, Therapeutic Targets, and Drug Development of Idiopathic Pulmonary Fibrosis.

Authors:  Hongbo Ma; Xuyi Wu; Yi Li; Yong Xia
Journal:  Front Pharmacol       Date:  2022-07-21       Impact factor: 5.988

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.